To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.
Do you support it?
Want to know if it passes?
We'll email you when HR 6348 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 6348.
You're tracking HR 6348
We'll email you the moment it moves.
HR 6348 — To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.
Last action — Referred to the House Committee on Energy and Commerce.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
To extend for two years the program for priority review to encourage treatments for rare pediatric diseases. This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2018 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)
Bill Text
We don't have the full text on file for this bill yet.
Read HR 6348 on the official United States source →Action History
-
Referred to the House Committee on Energy and Commerce.
-
Introduced in House
Sponsors
- Alan Grayson · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 6348 do?
- To extend for two years the program for priority review to encourage treatments for rare pediatric diseases. This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2018 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)
- Who sponsors HR 6348?
- HR 6348 is sponsored by Alan Grayson (D).
- What is the current status of HR 6348?
- This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 6348?
- Track HR 6348 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 6348
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 6348
Last checked for changes about 17 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →